CN1750814A - 多层片形式的口香糖 - Google Patents
多层片形式的口香糖 Download PDFInfo
- Publication number
- CN1750814A CN1750814A CNA2004800044682A CN200480004468A CN1750814A CN 1750814 A CN1750814 A CN 1750814A CN A2004800044682 A CNA2004800044682 A CN A2004800044682A CN 200480004468 A CN200480004468 A CN 200480004468A CN 1750814 A CN1750814 A CN 1750814A
- Authority
- CN
- China
- Prior art keywords
- tablet
- layer
- active component
- excipient
- stick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015218 chewing gum Nutrition 0.000 title description 23
- 229940112822 chewing gum Drugs 0.000 title description 22
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 238000007906 compression Methods 0.000 claims abstract description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 23
- 230000006835 compression Effects 0.000 claims abstract description 22
- 235000005911 diet Nutrition 0.000 claims abstract description 3
- 238000007907 direct compression Methods 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000011159 matrix material Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 20
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 239000005913 Maltodextrin Substances 0.000 claims description 11
- 229920002774 Maltodextrin Polymers 0.000 claims description 11
- 229940035034 maltodextrin Drugs 0.000 claims description 11
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229960001855 mannitol Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 5
- 229940043353 maltol Drugs 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 239000006041 probiotic Substances 0.000 claims description 5
- 230000000529 probiotic effect Effects 0.000 claims description 5
- 235000018291 probiotics Nutrition 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 239000003172 expectorant agent Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229960002160 maltose Drugs 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 230000001539 anorectic effect Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 210000000748 cardiovascular system Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 230000002048 spasmolytic effect Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 68
- 238000002360 preparation method Methods 0.000 description 46
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 14
- 230000001055 chewing effect Effects 0.000 description 12
- 239000008119 colloidal silica Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 9
- 229960001948 caffeine Drugs 0.000 description 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 9
- 230000009969 flowable effect Effects 0.000 description 9
- 239000008240 homogeneous mixture Substances 0.000 description 9
- 108010011485 Aspartame Proteins 0.000 description 8
- 239000000605 aspartame Substances 0.000 description 8
- 235000010357 aspartame Nutrition 0.000 description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 8
- 229960003438 aspartame Drugs 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229960004205 carbidopa Drugs 0.000 description 6
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 6
- 229960004502 levodopa Drugs 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 5
- 229960004203 carnitine Drugs 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- VHFPVEGFRVEDBK-SNAWJCMRSA-N (e)-3-(6-methylsulfanyl-4-oxoquinazolin-3-yl)prop-2-enoic acid Chemical compound N1=CN(\C=C\C(O)=O)C(=O)C2=CC(SC)=CC=C21 VHFPVEGFRVEDBK-SNAWJCMRSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- CWWCQGGNKDBSNT-UHFFFAOYSA-N 2-(2-phenoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=CC=C1 CWWCQGGNKDBSNT-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- RZCJLMTXBMNRAD-UHFFFAOYSA-N 4-(2-aminopropyl)phenol;hydrobromide Chemical compound Br.CC(N)CC1=CC=C(O)C=C1 RZCJLMTXBMNRAD-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KTNROWWHOBZQGK-UHFFFAOYSA-N Etilefrine hydrochloride (TN) Chemical compound [Cl-].CC[NH2+]CC(O)C1=CC=CC(O)=C1 KTNROWWHOBZQGK-UHFFFAOYSA-N 0.000 description 1
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 229920001386 Gefarnate Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- YGRFXPCHZBRUKP-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(C(O)C(C)N)=C1 YGRFXPCHZBRUKP-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- XPYHEGHESSCHSN-UHFFFAOYSA-N N1CCNCC1.[Br] Chemical compound N1CCNCC1.[Br] XPYHEGHESSCHSN-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- YSIITVVESCNIPR-UHFFFAOYSA-N Troxipide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC2CNCCC2)=C1 YSIITVVESCNIPR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- ALIXRWKJZYLBJI-UHFFFAOYSA-N [4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride Chemical compound Cl.CNCCC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1 ALIXRWKJZYLBJI-UHFFFAOYSA-N 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960005380 alfentanil hydrochloride Drugs 0.000 description 1
- MRDBGMJEPGXQHJ-UHFFFAOYSA-N almitrine dimesylate Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C=2N=C(NCC=C)N=C(NCC=C)N=2)CC1 MRDBGMJEPGXQHJ-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003108 brompheniramine maleate Drugs 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960001768 buspirone hydrochloride Drugs 0.000 description 1
- JPHRYPDSOKJAQQ-UHFFFAOYSA-N calcium;1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical compound [Ca].CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC JPHRYPDSOKJAQQ-UHFFFAOYSA-N 0.000 description 1
- UKLJMHXGZUJRTL-UHFFFAOYSA-L calcium;n-cyclohexylsulfamate Chemical compound [Ca+2].[O-]S(=O)(=O)NC1CCCCC1.[O-]S(=O)(=O)NC1CCCCC1 UKLJMHXGZUJRTL-UHFFFAOYSA-L 0.000 description 1
- 229960000926 camazepam Drugs 0.000 description 1
- PXBVEXGRHZFEOF-UHFFFAOYSA-N camazepam Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(OC(=O)N(C)C)N=C1C1=CC=CC=C1 PXBVEXGRHZFEOF-UHFFFAOYSA-N 0.000 description 1
- 229960002252 carbenoxolone sodium Drugs 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 description 1
- 229950002698 cathinone Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960003431 cetrimonium Drugs 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 1
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 1
- 229950009468 ciclazindol Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 1
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 229960001577 dantron Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 229960003829 desipramine hydrochloride Drugs 0.000 description 1
- XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- ICFXZZFWRWNZMA-UHFFFAOYSA-N diethylpropion hydrochloride Chemical compound [Cl-].CC[NH+](CC)C(C)C(=O)C1=CC=CC=C1 ICFXZZFWRWNZMA-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960005234 diphenoxylate hydrochloride Drugs 0.000 description 1
- ZNMWYBRBHINHJC-UHFFFAOYSA-N diphenylmethanone N-ethylethanamine hydrochloride Chemical compound C(C1=CC=CC=C1)(=O)C1=CC=CC=C1.C(C)NCC.Cl ZNMWYBRBHINHJC-UHFFFAOYSA-N 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003891 doxapram hydrochloride Drugs 0.000 description 1
- MBGXILHMHYLZJT-UHFFFAOYSA-N doxapram hydrochloride (anhydrous) Chemical compound [Cl-].C=1C=CC=CC=1C1(C=2C=CC=CC=2)C(=O)N(CC)CC1CC[NH+]1CCOCC1 MBGXILHMHYLZJT-UHFFFAOYSA-N 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001877 fenfluramine hydrochloride Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960003779 gefarnate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- MJKMHVIKCKUYTR-UHFFFAOYSA-N hydron;1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol;dichloride Chemical compound Cl.Cl.C=1C=CC=CC=1C(OC)CN(CC1)CCN1CC(O)C(OC)C1=CC=CC=C1 MJKMHVIKCKUYTR-UHFFFAOYSA-N 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 229940018465 hydroxyamphetamine hydrobromide Drugs 0.000 description 1
- 229960001216 ibopamine hydrochloride Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- PBJNZCQJMWVIRT-MDQYBHOLSA-N inosine pranobex Chemical compound CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C2=NC=NC(O)=C2N=C1 PBJNZCQJMWVIRT-MDQYBHOLSA-N 0.000 description 1
- 229960000476 inosine pranobex Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960003221 levopropoxyphene Drugs 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- VENXSELNXQXCNT-IJYXXVHRSA-N metaraminol bitartrate Chemical compound [H+].[H+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 VENXSELNXQXCNT-IJYXXVHRSA-N 0.000 description 1
- 229960002984 metaraminol bitartrate Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 229960004269 methoxamine hydrochloride Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004843 mianserin hydrochloride Drugs 0.000 description 1
- YNPFMWCWRVTGKJ-UHFFFAOYSA-N mianserin hydrochloride Chemical compound [H+].[Cl-].C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 YNPFMWCWRVTGKJ-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- PLYSCVSCYOQVRP-UHFFFAOYSA-N midazolam hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F PLYSCVSCYOQVRP-UHFFFAOYSA-N 0.000 description 1
- 229960002853 midazolam hydrochloride Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- KVCJCEKJKGLBOK-UHFFFAOYSA-N morclofone Chemical compound COC1=CC(C(=O)C=2C=CC(Cl)=CC=2)=CC(OC)=C1OCCN1CCOCC1 KVCJCEKJKGLBOK-UHFFFAOYSA-N 0.000 description 1
- 229960001244 morclofone Drugs 0.000 description 1
- 229960005250 naloxone hydrochloride Drugs 0.000 description 1
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 1
- 229940099751 naphcon Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229960005382 phenolphthalein Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229960002808 pholcodine Drugs 0.000 description 1
- GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229960000786 propylhexedrine Drugs 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960000230 sobrerol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- IQWYAQCHYZHJOS-UHFFFAOYSA-N tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 description 1
- 229960005214 tetrazepam Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229950011055 tiacrilast Drugs 0.000 description 1
- OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000315 trifluoperazine hydrochloride Drugs 0.000 description 1
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229960001341 troxipide Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/0002—Processes of manufacture not relating to composition and compounding ingredients
- A23G3/0063—Coating or filling sweetmeats or confectionery
- A23G3/0065—Processes for making filled articles, composite articles, multi-layered articles
- A23G3/007—Processes for making filled articles, composite articles, multi-layered articles the material being shaped at least partially in a mould, in the hollows of a surface, a drum, an endless band or by drop-by-drop casting or dispensing of the materials on a surface or an article being completed
- A23G3/008—Compression moulding of paste, e.g. in the form of a ball or rope or other preforms, or of powder or granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/02—Apparatus specially adapted for manufacture or treatment of chewing gum
- A23G4/04—Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/02—Apparatus specially adapted for manufacture or treatment of chewing gum
- A23G4/04—Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping
- A23G4/043—Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping for composite chewing gum
- A23G4/046—Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping for composite chewing gum with a centre made of chewing gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/126—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/18—Chewing gum characterised by shape, structure or physical form, e.g. aerated products
- A23G4/20—Composite products, e.g. centre-filled, multi-layer, laminated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
Abstract
公开了具有三明治样结构的包含至少一层包含一种或多种药学、饮食或营养学活性成分的胶状基质的内层和两个不连续的包含防止粘附到压片机的冲上的抗粘赋形剂和压缩助剂以及可能的与存在于所说内层中的活性成分相同或不同的活性成分的外层的片剂。所说的片剂是通过将各层的各种组分的混合物或颗粒直接压缩获得的。
Description
本发明涉及可以通过直接压缩获得的多层片形式的口香糖。
现有技术
口香糖正被越来越多地用作传递药学或营养学活性成分的方法。典型的制造方法需要在适宜的混合器中将基础胶状物加热至软化温度或者将其在大约80℃的温度下熔化;向该被熔化的物质中加入诸如增塑剂、甜味剂、矫味剂之类的组分和该制剂中可能的其它活性组分。在混合后,将所得的物质拉成条状,冷却并将其切割成一定大小。
虽然这种制造方法可用于耐热的产品,但是其不易用来制备携带不耐热物质如大多数药物和特定的活性物质如益生菌的系统。
为了克服这些限制因素,已经提出了许多口香糖的制造方法,如在US6,423,336(2002年7月23日)和WO 02/051258(2002年7月4日)中所述的方法。最近对用压缩法获得的包含牙齿卫生保健产品(专利申请US2002/0071858;2002年6月13日)、呼吸清新物质(US2002/0122843;2002年9月5日)和类药营养品(nutraceutical)物质(EP1254664;2002年11月6日)的口香糖进行了描述。但是,在所有这些专利中,制造方法的描述都十分含糊,并且都没有谈到在对该胶状混合物进行压缩的过程中所发生的问题。在对胶状物质进行压缩的过程中遇到的一个主要的并且有时难以克服的问题是当对所说的胶状基质进行压缩时,该被压紧的物质强烈粘附到尤其是压片机的上下冲上,从而造成了大规模制备操作的速度和质量问题。由于该胶状基质本身的特性就是粘性的并且是该制剂的最大组成部分,所以这种现象特别明显;此外,该压缩过程放大了所说材料的这种行为。这些问题使得制造过程十分困难,并且一般需要十分低的生产速度和使用复杂的压片冷却系统。例如在US 4139589中公开了该类方法中的一种,其公开了包含一种颗粒状塑性胶状基质的核和非塑性片剂物质的外层的多层片的制备。为了防止塑性材料粘附到冲上,其提出将所说的塑性材料冷却至大约-10℃和/或使用独立和顺序进行的压片步骤,这极大地限制了该过程的效率。此外,该片剂的表面既不规则又不均匀。需要另外的包衣和/或包膜法来掩盖这种缺陷,从而增加了制造成本。
WO 02/102357公开了其中包含活性成分烟碱的胶状基质的核心被完全包埋到缓冲的包衣层中的咀嚼产品。所说的咀嚼产品不涉及任何压片步骤并且仅需要对用常规方法获得的预先形成的胶核进行包衣的步骤。WO96/03111公开了包含任选地为包含被成膜的纤维素和聚乙二醇包覆着的胶状基质核的微球形式的药物组合物。该文献还公开了一种制备所说组合物的方法,其包括将所说的胶状物冷冻以获得可进行加工的颗粒。
本发明的描述
现在已经发现,可以通过制备包含一种或多种药学、饮食或营养学活性成分的直接压缩的片剂来克服所说现有技术的缺陷,所说的片剂包含至少一层胶状基质的内层和至少一层包含抗粘赋形剂和/或压缩助剂的外层。
术语“抗粘赋形剂和压缩助剂”指的是能在胶状基质内层上涂覆一层或多层可促进系统的压缩过程并防止冲粘附到压片机上的层的任何物质或物质混合物。
在压缩过程中仅外层与冲进行接触并解决了粘附过程。
该类抗粘赋形剂的实例包括异麦芽酮糖醇(isomalt)、麦芽酚、麦芽糖糊精、麦芽糖醇、甘露醇、木糖醇、乳糖醇、乳糖、脱脂乳、赤藓糖醇(eritritol)、低聚果糖、回生淀粉(retrograded starch)、聚山梨醇酯类物质、聚氧乙烯、右旋糖酐、环糊精、低聚蔗糖(oligosaccarose)、果糖、氢化淀粉hydrosilates。
特别优选的是异麦芽酮糖醇、麦芽糖糊精、麦芽糖醇、甘露醇、木糖醇、乳糖醇、脱脂乳、赤藓糖醇、果糖、低聚果糖、右旋糖酐、低聚蔗糖。
更优选的是异麦芽酮糖醇、麦芽糖糊精、麦芽糖醇、甘露醇、木糖醇、脱脂乳、低聚果糖。
本发明的片剂优选由一层包含胶状基质和活性物质的中间层和两层包含所说的抗粘赋形剂和压缩赋形剂的外层所组成。
由该制造方法制备的本发明的片剂具有一种三明治样结构,所说的外层彼此不相接触并且仅分别包覆所说胶状核的顶部和底部,使得其外周的侧面未被包覆。
图1和2分别表示了本发明三层片的侧视图和透视图,其中数字1和3表示包含抗粘赋形剂的顶层包衣和底层包衣,而数字2表示所说的胶状核。
或者,该片剂可包含两层、三层或多层胶状基质的内层,其各自可包含与存在于其它层中的活性成分相同或不同的活性成分,或者可以由其唯一的功能是将含有不相容活性物质的层分割开的制剂来进行构建。
外层是所说制剂在压缩过程中与冲进行接触的唯一部分,从而完全解决了所有的粘附问题,并且克服了在仅对胶状基质进行压缩的过程中遇到的困难,特别是不再需要将该胶状物进行冷冻以对其进行制粒并随后与其它成分和赋形剂混合压缩。本发明还使得可以用常规压片机连续高速地进行制造。本发明的另一个优点是胶状基质及其所携带的活性物质在制造过程中不被加热,并且在压缩阶段被外层保护起来。
本发明的方法可以携带不耐热的物质如药物、生物学活性物质、益生菌、益生元、营养品、食品和甜食物质,并且还可以同时携带其它物质。
外层也可以包含与中间层中所含的活性成分相同或不同的活性成分。
包含于本发明片剂的一层或多层中的药物的实例包括镇痛剂、退热剂、麻醉剂、抗变态反应剂、抗炎剂、抗真菌剂和支气管扩张药、抗生素、作用于心血管系统的药物、减充血剂、消毒剂、祛痰剂、粘液溶解剂、镇咳药、减食欲物质和解痉剂、以及益生菌、益生元、酶等等。
所说药物的特定实例包括乙酰水杨酸、金诺芬、苄达酸、苄达明、双氯芬酸、二氟尼柳、依托度酸、芬布芬、非诺洛芬钙、氟比洛芬、布洛芬、吲哚美辛、酮洛芬、酮咯酸氨基丁三醇、甲芬那酸、萘普生、尼美舒利、对乙酰氨基酚、保泰松、吡罗昔康、舒林酸和舒洛芬;乙酰半胱氨酸、盐酸氨溴索、溴己新、羧甲半胱氨酸、右美沙芬、愈创木酚甘油醚、吐根、左丙氧芬、半胱甲酯、吗氯酮、福尔可定、potassium guaicolsulphonate、索布瑞醇和盐酸双苯哌丙醇;阿米三嗪二甲磺酸盐、安非他明、卡尼汀、乙酰卡尼汀、盐酸苯嘧吲哚、硫酸右苯丙胺、盐酸右芬氟拉明、盐酸安非拉酮、盐酸多沙普仑、盐酸芬氟拉明、盐酸苄非他明、卡西酮、右芬氟拉明、盐酸二乙胺苯酮、奥利司他、西布曲明、西地那非、盐酸阿朴吗啡、他达那非、伐地那非、盐酸哌甲酯、甲基安非他明、匹莫林、卡地阿唑、fentermine、丙己君;苯扎氯铵、苄索氯铵、溴化十六烷基三甲胺、西曲溴铵、西吡氯铵、氯己定以及其盐、氯甲酚、对氯间二甲酚、chlorophene、甲酚、地喹氯铵、度米芬、海克替啶、己雷琐辛、富马酸酮替芬、奈多罗米钠、色甘酸钠、硫克司特、阿普唑仑、异戊巴比妥、溴哌立多、盐酸丁螺环酮、卡马西泮、利眠宁、氯美噻唑、氯丙嗪、氧巴占、氯氮平、地西泮、氟哌利多、氟硝西泮、氟奋乃静癸酸酯、氟哌啶醇、氟西泮、劳拉西泮、洛沙平、甲喹酮、盐酸咪达唑仑、硝西泮、奋乃静、普鲁氯嗪、丙嗪、舒必利、替马西泮、佐匹克隆;盐酸三氟拉嗪、四氢西泮、泰必利、盐酸多巴胺、盐酸麻黄碱、ethylephrine hydrochloride、氢溴酸非诺特罗、盐酸异波帕明、氢溴酸羟苯丙胺、异丙肾上腺素、酒石酸间羟胺、盐酸甲氧明、盐酸萘甲唑啉、盐酸去甲肾上腺素、盐酸苯丙醇胺、沙丁胺醇、舒丁喘宁、盐酸奥昔布宁、溴丙胺太林、盐酸纳洛酮、盐酸纳曲酮、阿莫西林、氨苄青霉素、阿齐霉素、两性霉素、盐酸氨苄青霉素碳酯、头孢克洛、头孢呋肟酯、环丙沙星、克拉霉素、盐酸克林霉素、盐酸多西环素、夫西地酸、米诺环素、诺氟沙星、利福平、氟康唑、伊曲康唑、制霉菌素、阿昔洛韦、异丙肌苷、利巴韦林、齐多夫定、皮质类固醇、倍他米松、地塞米松、氢化可的松、甲泼尼龙、泼尼松龙、曲安西龙、盐酸阿米替林、盐酸氯米帕明、盐酸地昔帕明、盐酸多塞平、盐酸氟西汀、盐酸丙咪嗪、盐酸米安色林、盐酸去甲替林、盐酸曲唑酮、色氨酸;维生素或广义的维生素物质、必需氨基酸、酶、辅酶、酵母菌、益生菌、益生元、营养的和饮食添加物草药提取物、蜂胶、氟化钠、比沙可啶、甘珀酸钠、药鼠李提取物、西米替丁、西沙必利、丹蒽醌、盐酸地芬诺酯、多库酯钙、多潘立酮、法莫替丁、吉法酯、乳果糖、洛派丁胺、兰索拉唑、美沙拉嗪、盐酸甲氧氯普胺、乙硫异烟胺、奥美拉唑、酚酞、雷尼替丁、番泻叶、硫糖铝、柳氮磺吡啶、曲昔匹特、阿伐斯汀、阿司咪唑、马来酸溴苯那敏、马来酸卡比沙明、马来酸氯苯那敏、盐酸赛庚啶、茶苯海明、苯海拉明、琥珀酸多西拉敏、盐酸氟桂利嗪、美吡拉敏、异丙嗪、特非那定、tripenellamine、曲普利啶、阿昔莫司、苯扎贝特、氯贝特、非诺贝特、吉非贝特、洛伐他汀、普罗布考、辛伐他汀和广义的他汀类物质、盐酸阿芬他尼、盐酸丁丙诺啡、可待因、右丙氧芬、盐酸美沙酮、喷他佐辛、黄嘌呤类物质如氨茶碱、咖啡因、二羟丙茶碱、茶碱、双硫仑、银杏、木瓜蛋白酶、胃蛋白酶、泛癸利酮和缬草提取物。
这些成分可以单独或者联合被包含在所说口香糖的单层中,或者可以被携带在许多层中。活性组分的含量可以为携带所说活性物质的层重量的0.5%至90%,并且优选地为2至60%。
可以用具有20%至98%,优选30至90%重量的胶含量的具有不同特性和复杂组成的胶状基质来制备口香糖。可以加入选自多元醇如山梨醇、木糖醇、麦芽糖醇、异麦芽酮糖醇、麦芽酚、甘露醇、麦芽糖糊精和环糊精的增塑剂以获得具有最佳的感官特性和咀嚼特性的口香糖。所说增塑剂的存在百分比为0.5至70.0%重量,并且优选地为1.0至50.0%重量。
多层口香糖是通过对粉末和/或颗粒的混合物进行压缩来制备的;可以先对一些组分或组分的混合物进行常规处理如湿法制粒或干法制粒。优选使用多漏斗的旋转压片机,例如对于三层片而言将使用三漏斗机器:在一个漏斗中装填胶状基质组合物,而其它两个漏斗将装填抗粘赋形剂。对该机器进行适当编程从而使其首先将抗粘赋形剂从第一个漏斗中饲料到压缩冲模中,然后将胶状基质从第二个漏斗中饲料到冲模中,然后再将抗粘赋形剂从第三个漏斗中饲料到冲模中。位于所说的第一个和第三个漏斗中的赋形剂可以相同或不同。可以在室温下进行所说的过程。
除上述抗粘赋形剂外,各层的配方中可包含制药工业中常用的其它压缩助剂,如乳糖、淀粉、改性淀粉、微晶纤维素、山梨醇、环糊精、蔗糖、果糖、葡萄糖、滑石粉、胶态二氧化硅、硬脂酸镁、淀粉糊、甲基纤维素、乙基纤维素、聚乙烯吡咯烷酮、明胶、果胶和其它已知的助剂。
还可以加入甜味剂如蔗糖、糖精、糖精钠、阿司帕坦、乙酰舒泛酸以及其钾盐、环己氨磺酸、环己氨磺酸钙、环己氨磺酸钠、甘草酸铵以及食品和制药工业中常用的其它甜味剂,如低聚糖、果糖、葡萄糖、乳糖、葡萄糖、麦芽糖醇、麦芽酚、麦芽糖糊精、甘露醇、山梨醇和木糖醇。所说甜味剂存在的重量百分比为0.5至50.0%,优选1.0至25.0%,并且更优选地为2至15%。该制剂还可以包含0.5至20.0%,优选2至10.0%重量的矫味剂。
将用下面的实施例来对本发明进行更详细的说明。
实施例1
在中间层中包含100mg乙酰半胱氨酸的三层片的制备。
1-a外层用混合物的制备
各外层具有下面的单位组成:
木糖醇(Xylisorb) 100.00mg
麦芽糖糊精 100.00mg
滑石粉(C.Erba) 5.00mg
硬脂酸镁(C.Erba) 5.00mg
胶态二氧化硅(Syloid 244-Grace) 2.00mg
薄荷矫味剂(Peppermint) 5.00mg
总重量 217.00mg
将木糖醇+麦芽糖糊精混合10分钟。然后加入剩余的组分,再继续混合20分钟以制备一种均匀的混合物。
1-b组成中间层的混合物的制备
该内层具有下面的单位组成:
乙酰半胱氨酸(Moehs) 100.00mg
胶状基质(Flarer-PG Mondo TA) 500.00mg
滑石粉(C.Erba) 10.00mg
硬脂酸镁(C.Erba) 10.00mg
胶态二氧化硅(Syloid 244-Grace) 5.00mg
薄荷矫味剂(Peppermint) 5.00mg
阿司帕坦 4.00mg
总重量 634.00mg
将活性组分和胶状基质与矫味剂、阿司帕坦以及滑石粉混合,继续混合10分钟。然后,加入其它的赋形剂,再继续混合20分钟,制得一种可流动的均匀混合物。
1-c通过压缩进行的三层口香糖的制备
将根据众所周知的制造方法并如1-a和1-b段所述那样获得的粉末混合物装填到适于制备三层片的旋转压片机(例如Manesty Layer-Press,Liverpool,UK)的三个装料漏斗中。具体地讲,将1-a段中所述的混合物装填到第一个和第三个漏斗中,并将1-b段中所述的混合物装填到第二个漏斗中。所说的压片机配有直径为13.0mm的圆形平面冲。调节所说的机器,制备由217mg 1-a段中所述混合物的第一层、634mg(包含100mg乙酰半胱氨酸)的第二层、以及217mg 1-a段中所述混合物的第三层并且也是最后一层所组成的三层片。第一和第三层中所含的量足以并且必需产生厚度约1.5mm的所述层。因此,该最终的系统的总重量为1068.00mg,相当于100mg乙酰半胱氨酸的含量。由于存在该将胶层和压片机机械部分之间的接触面积最小化的外层,所以该压缩过程毫无困难,具有高产量,并且不会粘冲。在与机械部分直接接触的胶状基质混合物的压缩阶段存在的一个不能解决的问题是强力粘附,其可造成冲-冲模系统卡死并且在制备片剂时可能使得不能取出所说的片剂,从而使得该过程不能用于工业规模。用该实施例所述的新方法获得的片剂具有光滑、有光泽的表面。在咀嚼时其感官特性如下:令人愉快的味道且成胶时间迅速。在咀嚼时,该口香糖具有极佳的稠度,既使长时间咀嚼时也是如此,并且可咀嚼的体积很合适。没有遗后味觉。
参考实施例1b
为了仅对该包含活性成分的层的压缩特性进行试验,制备具有包含100mg乙酰半胱氨酸的单层的片剂。
1-bis-a 使用实施例1的1-b段中所述的组成。
1-bis-b 通过压缩进行的单层口香糖的制备。
将根据众所周知的方法并如上所述那样获得的粉末混合物装填到旋转压片机(例如Korsch,Cologne,德国)的装料漏斗中。所说的压片机配有直径为13.0mm的圆形平面冲。调节将该机器,制备634mg的片剂(包含100mg乙酰半胱氨酸)。
由于在压缩过程中遇到了困难而不能获得片剂。将所说的材料压实,但是所制备的片剂仍然粘在上冲或下冲之一上。因为不能用压片机的自动装置取下片剂,所以必需立即中断制备过程;仅能用解剖刀或其它适宜的工具手工取出所制备的片剂,并且需要付出相当大的努力。在该操作过程中,片剂破碎,并且生产不能继续。因为被压缩材料的一部分被粘附到上冲上,一部分被粘附到下冲上,所以产生的另一个问题是片剂的脱盖。该比较试验的结果证明了用胶状基质制造片剂的困难性。
实施例2
在中间层中包含100mg肉毒碱的三层片的制备
2-a外层用混合物的制备
各外层具有下面的单位组成:
麦芽糖糊精 200.00mg
滑石粉(C.Erba) 5.00mg
硬脂酸镁(C.Erba) 3.00mg
胶态二氧化硅(Syloid 244-Grace) 1.00mg
乙酰舒泛 3.00mg
橙矫味剂(Givaudan) 5.00mg
总重量 217.00mg
将下面的物质在Turbula中混合10分钟:麦芽糖糊精+二氧化硅;然后加入剩余的组分,并且再继续混合20分钟。得到一种可流动的均匀混合物。
2-b组成中间层的混合物的制备
该内层具有下面的单位组成:
肉毒碱 100.00mg
胶状基质(Flarer-PG Mondo TA) 500.00mg
滑石粉(C.Erba) 10.00mg
硬脂酸镁(C.Erba) 10.00mg
胶态二氧化硅(Syloid 244-Grace) 5.00mg
橙矫味剂(Givaudan) 5.00mg
阿司帕坦 4.00mg
总重量 634.00mg
将矫味剂、阿司帕坦以及滑石粉加入到胶中并继续混合10分钟。然后,加入其它赋形剂和活性组分并再继续混合20分钟,制得一种可流动的均匀混合物。
2-c通过压缩进行的三层口香糖的制备
将根据众所周知的制备方法并如2-a和2-b段所述那样获得的粉末混合物装填到适于制备三层片的旋转压片机(例如Manesty Layer-Press,Liverpool,UK)的三个装料漏斗中。具体地讲,将2-a段所述的混合物装填到第一个和第三个漏斗中,并且将2-b段所述的混合物装填到第二个漏斗中。所说的压片机配有直径为13.0mm的圆形平面冲。调节该机器,制备由217mg 2-a段所述混合物的第一层、634mg(相当于100mg肉毒碱)的第二层、以及217mg 2-a段所述混合物的第三层并且也是最后一层所组成的三层系统。第一和第三层中所包含的量足以并且必需产生厚度约1.5mm的所述层。
因此,该最终的系统的总重量为1068mg,相当于100mg的肉毒碱含量。该压缩过程在高制备速度下可以毫无困难地进行,不粘冲。该试验证实了该创新的剂型和方法使得可以有效进行工业生产。
所得的片剂(口香糖)具有光滑、有光泽的表面。在咀嚼时其感官特性如下:可接受的味道、成胶迅速、极佳的稠度、没有遗后味觉。
实施例3
在中间层中包含10mg咖啡因的三层片的制备
3-a外层用混合物的制备
各外层具有实施例1a中所述的单位组成。
3-b组成中间层的混合物的制备
该内层具有下面的单位组成:
咖啡因(C.Erba) 10.00mg
胶状基质(Flarer-PG Mondo TA) 500.00mg
滑石粉(C.Erba) 10.00mg
硬脂酸镁(C.Erba) 10.00mg
胶态二氧化硅(Syloid 244-Grace) 5.00mg
薄荷矫味剂(Peppermint) 10.00mg
阿司帕坦 5.00mg
总重量 550.00mg
将矫味剂、阿司帕坦以及滑石粉加入到混有咖啡因的胶状基质中并继续混合10分钟。然后向其中加入其它的赋形剂并再继续混合20分钟,制得一种可流动的均匀混合物。
3-c通过压缩进行的三层口香糖的制备
将根据众所周知的制备方法并如3-a和3-b段所述那样获得的粉末混合物装填到适于制备三层片的旋转压片机(例如Manesty Layer-Press,Liverpool,UK)的三个装料漏斗中。因此,该最终的系统的总重量为984.00mg,相当于10mg的咖啡因含量。
该压缩过程在高制备速度下可以毫无困难地进行,不粘冲。所得的片剂具有光滑、有光泽的表面。在咀嚼时其感官特性如下:可接受的味道、成胶时间十分迅速、具有适宜的可咀嚼体积和极佳的稠度、以及略苦的遗后味觉。
3-d对活性组分的体内释放进行的评估.
为了确定活性组分从该口香糖中的释放,用包含3名志愿者的小组对该片剂进行试验。对于各试验而言,让所说的志愿者咀嚼一片口香糖并咀嚼设定的时间。在该段时间后,对该口香糖进行研磨并对活性组分的含量进行分析。用下面的咀嚼时间进行体内试验:5、10、15、20、30和40分钟。对该口香糖残余物称重、冷冻并仔细研磨。然后,用1000mL 37℃的水作为溶出液,根据美国药典对精确重量的这种粉末进行溶出试验,桨速为100rpm。用分光光度法来进行该试验,在273nm下进行操作。通过从存在于所说药学形式中的咖啡因含量中减去位于残余物中的咖啡因含量来确定在体内所释放的活性组分的量。
表I表示了在不同咀嚼时间后所释放咖啡因的百分比。
表I
咀嚼时间 | 志愿者1 | 志愿者2 | 志愿者3 | 在体内所释放的咖啡因(均值) | SD |
5分钟 | 71.52 | 77.02 | 75.07 | 74.54 | 2.79 |
10分钟 | 86.03 | 83.66 | 84.94 | 84.88 | 1.19 |
15分钟 | 90.18 | 90.97 | 91.07 | 90.74 | 0.49 |
20分钟 | 89.45 | 91.38 | 89.61 | 90.21 | 1.19 |
30分钟 | 93.92 | 92.25 | 92.49 | 92.89 | 0.90 |
40分钟 | 92.79 | 93.34 | 92.34 | 92.82 | 0.50 |
可以看出,在咀嚼5分钟后,释放了药物剂量的约75%,在15分钟后,90%以上的活性组分被充分释放。再咀嚼25分钟对该口香糖所释放的活性组分的量不会有任何显著改变。该体内结果证实了在该药学剂型中所包含的活性组分易于被吸收。正如低标准偏差所证明的那样,各试验的结果具有高再现性,其证实了药物从该合药口香糖中的释放不依赖于志愿者的咀嚼功效,并且因此确保了这种创新药学形式的实用性。
实施例4
在中间层中包含3mg盐酸苄达明的三层片(口香糖)的制备。
4-a外层用混合物的制备
各外层具有下面的百分比组成:
异麦芽酮糖醇 85.10%
果糖(C.Erba) 7.66%
滑石粉(C.Erba) 2.13%
胶态二氧化硅(Syloid 244-Grace) 0.85%
硬脂酸镁(C.Erba) 2.13%
薄荷矫味剂(Givaudan Roure) 2.13%
总重量 100.00%
将所有其它组分加入到异麦芽酮糖醇和胶态二氧化硅的混合物中并继续混合20分钟,制得一种可流动的均匀混合物,随后将其进行下述压缩步骤。
4-b组成中间层的混合物的制备
所说的中间层具有下面的单位组成:
盐酸苄达明 3.00mg
胶状基质(Flarer-PG Mondo TA) 450.00mg
滑石粉(C.Erba) 5.00mg
胶态二氧化硅(Syloid 244-Grace) 2.00mg
硬脂酸镁(C.Erba) 5.00mg
薄荷矫味剂(Givaudan Roure) 5.00mg
柠檬矫味剂(Givaudan Roure) 10.00mg
阿司帕坦 10.00mg
总重量 490.00mg
将事先用25目筛网(等于710微米)进行了筛分的所有组分倒入适宜的混合器中,并在搅拌20分钟后,得到一种可流动的均匀混合物,将其进行4-c段中所述的压缩步骤。
4-c通过压缩进行的三层片的制备
将根据众所周知的制备方法并如4-a和4-b段所述那样获得的粉末混合物装填到适于制备三层片的旋转压片机(例如Manesty Layer-Press,Liverpool,UK)的三个装料漏斗中。该最终的系统的总重量为990mg,相当于3mg的盐酸苄达明含量。该压缩过程在高制备速度下可以毫无困难地进行,不粘冲。所得的片剂具有光滑、有光泽的表面。在咀嚼时其感官特性如下:成胶时间迅速、具有适宜的可咀嚼体积和极佳的稠度、味道略涩、没有遗后味觉。
实施例5
在第2层中包含50mg左旋多巴和在第3层中包含12.5mg卡比多巴的四层片的制备。
5-a用于第一层和第四层的混合物的制备
各层具有下面的单位组成:
低聚果糖 150.00mg
果糖(C.Erba) 10.00mg
滑石粉(C.Erba) 5.00mg
胶态二氧化硅(Syloid 244-Grace) 1.00mg
硬脂酸镁(C.Erba) 2.00mg
巧克力矫味剂(Givaudan Roure) 10.00mg
榛子矫味剂(Givaudan Roure) 5.00mg
总重量 183.00mg
将所有预先进行了筛分的组分置于适宜的容器中并将其混合20分钟。然后,将该可流动的均匀混合物进行下述压缩步骤。
5-b组成中间层的混合物的制备
该中间层具有下面的单位组成:
左旋多巴 50.00mg
胶状基质(Flarer-Unique 90%) 250.00mg
滑石粉(C.Erba) 2.00mg
胶态二氧化硅(Syloid 244-Grace) 0.50mg
硬脂酸镁(C.Erba) 1.00mg
巧克力矫味剂(Givaudan Roure) 5.00mg
总重量 308.50mg
将事先用25目筛网(等于710nm)进行了筛分的所有组分倒入适宜的混合器中,在搅拌20分钟后,得到一种可流动的均匀混合物,将其进行5-d段所述的压缩步骤。
5-c组成中间层的混合物的制备
该中间层具有下面的单位组成:
卡比多巴 12.50mg
胶状基质(Flarer-Unique 90%) 250.00mg
滑石粉(C.Erba) 2.00mg
胶态二氧化硅(Syloid 244-Grace) 0.50mg
硬脂酸镁(C.Erba) 1.00mg
巧克力矫味剂(Givaudan Roure) 5.00mg
总重量 271.00mg
将事先用25目筛网(等于710nm)进行了筛分的所有组分倒入适宜的混合器中,在搅拌20分钟后,得到一种可流动的均匀混合物,将其进行5-d段所述的压缩步骤。
5-d通过压缩进行的四层片的制备
将根据众所周知的制备方法并如5-a、5-b和5-c段所述那样获得的粉末混合物装填到适于制备多层片的旋转压片机(例如 Korsch)的装料漏斗中。具体地讲,将5-a段所述的混合物装料到第一个和第四个漏斗中,将5-b段所述的混合物装料到第二个漏斗中,并将5-c段所述的混合物装料到第三个漏斗中。该压片机配有直径为12.0mm的圆形凸面冲并对其进行调节以制备由183mg 5-a的混合物的第一层、308.5mg(等于50mg左旋多巴)的第二层、271mg(等于12.5mg卡比多巴)的第三层、以及183mg 5-a段所述混合物的第四层所组成的四层系统。第一和第四层中所包含的量足以并且必须产生厚度约1.5mm的所述层。因此,该最终的系统的总重量为945mg,相当于50mg左旋多巴和12.5mg卡比多巴的含量。该压缩过程在高制备速度下可以毫无困难地进行,不粘冲。所得的片剂具有光滑、有光泽的表面。在咀嚼时,该片剂成胶时间迅速、具有适宜的可咀嚼体积和极佳的稠度、味道略涩并且没有遗后味觉。
然后,用1000mL 37℃的水作为溶出液,根据美国药典的方法对该片剂进行溶出试验,桨速为100rpm。用分光光度法来进行该试验,在280nm下进行操作。
表II表明了该片剂所释放的左旋多巴和卡比多巴的百分比。
表II
时间(分钟) | 左旋多巴 | 左旋多巴的SD | 卡比多巴 | 卡比多巴的SD |
0 | 0.00 | 0.00 | 0.00 | 0.00 |
5 | 63.52 | 8.08 | 78.23 | 2.54 |
15 | 90.00 | 4.74 | 92.63 | 0.96 |
20 | 92.47 | 4.46 | 94.97 | 0.74 |
25 | 94.04 | 4.08 | 96.55 | 0.82 |
30 | 94.90 | 4.01 | 98.18 | 0.71 |
35 | 95.66 | 3.92 | 98.77 | 0.77 |
40 | 96.28 | 3.84 | 100.00 | 0.00 |
Claims (11)
1.包含一种或多种药学、饮食或营养学活性成分的片剂,其包含至少一层胶状基质的内层和多层包含防止粘附到压片机的冲上的抗粘赋形剂和压缩助剂的外层,所说的片剂具有一种三明治样结构,该包含所说抗粘赋形剂的外层彼此不相接触并且仅分别包覆所说胶核的顶部和底部,其周围的侧面未被包覆。
2.如权利要求1所述的片剂,其包含两层、三层或多层胶状基质的内层,这些胶状基质各自可包含与位于其它层中的活性成分相同或不同的活性成分。
3.如权利要求1-2中任意一项所述的片剂,其中所说的相同或不同的活性成分还存在于一层或多层包含抗粘赋形剂和压缩助剂的外层中。
4.如权利要求1-3中任意一项所述的片剂,其是通过将各层的不同组分的混合物或颗粒直接压缩获得的。
5.如权利要求1-4中任意一项所述的片剂,其中所说的活性成分选自镇痛剂、退热剂、麻醉剂、抗变态反应剂、抗炎剂、抗真菌剂和支气管扩张药、抗生素、作用于心血管系统的药物、减充血剂、消毒剂、祛痰剂、粘液溶解剂、镇咳药、减食欲物质、解痉剂、益生菌、益生元、酶和类药营养品草药提取物。
6.如权利要求1-5中任意一项所述的片剂,其中活性组分的含量为携带所说活性组分的层重量的0.5%至90%,并且优选为2至60%。
7.如权利要求1-6中任意一项所述的片剂,其中胶状基质层包含选自山梨醇、木糖醇、麦芽糖醇、异麦芽酮糖醇、麦芽酚、甘露醇、麦芽糖糊精和环糊精的增塑剂。
8.如权利要求7所述的片剂,其中所说增塑剂的存在百分比为0.5至70.0%重量。
9.如权利要求1-8中任意一项所述的片剂,其中所说的抗粘赋形剂选自异麦芽酮糖醇、麦芽酚、麦芽糖糊精、麦芽糖醇、甘露醇、木糖醇、乳糖醇、乳糖、脱脂乳、赤藓糖醇、低聚果糖、回生淀粉、聚山梨醇酯类物质、聚氧乙烯、右旋糖酐、环糊精、低聚蔗糖、果糖、氢化淀粉hydrosilates。
10.一种制备如权利要求1-9中任意一项所述的片剂的方法,其包括在室温下在一种多漏斗机器中将胶状基质组合物抗粘赋形剂直接压片,首先从第一个漏斗中将第一部分抗粘赋形剂饲料到压片机冲模中,然后从另一个漏斗中将胶状基质饲料,然后从第三个漏斗中将第二部分抗粘赋形剂饲料并将所形成的这些层进行压缩。
11.可通过权利要求10所述的方法获得的片剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03003813A EP1449525A1 (en) | 2003-02-20 | 2003-02-20 | chewing gum in the form of multi-layer tablets |
EP03003813.7 | 2003-02-20 | ||
PCT/EP2004/000371 WO2004073691A1 (en) | 2003-02-20 | 2004-01-20 | Chewing gum in the form of multi-layer tablets |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1750814A true CN1750814A (zh) | 2006-03-22 |
CN1750814B CN1750814B (zh) | 2010-05-12 |
Family
ID=32731548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800044682A Expired - Lifetime CN1750814B (zh) | 2003-02-20 | 2004-01-20 | 多层片形式的口香糖 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9216157B2 (zh) |
EP (2) | EP1449525A1 (zh) |
JP (1) | JP5214142B2 (zh) |
CN (1) | CN1750814B (zh) |
AT (1) | ATE380021T1 (zh) |
CA (1) | CA2518528C (zh) |
DE (1) | DE602004010493T2 (zh) |
ES (1) | ES2295817T3 (zh) |
WO (1) | WO2004073691A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102480990A (zh) * | 2009-08-19 | 2012-05-30 | 狮王株式会社 | 糖衣口香糖及糖衣口香糖的制造方法 |
CN102599324A (zh) * | 2012-03-16 | 2012-07-25 | 常熟市汇丰食品有限公司 | 一种芳香植物口香糖及其制备方法 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0216413D0 (en) * | 2002-07-15 | 2002-08-21 | Nestle Sa | Tabletted chewing gum sweet |
DK1578422T3 (da) | 2002-12-20 | 2007-07-02 | Niconovum Ab | Fysisk og kemisk stabilt nikotin-indeholdende partikelholdigt materiale |
AU2003214016A1 (en) * | 2003-02-04 | 2004-08-30 | Gumlink A/S | Compressed chewing gum tablet |
EP1449525A1 (en) | 2003-02-20 | 2004-08-25 | Cross Chem Llc | chewing gum in the form of multi-layer tablets |
DK1474995T3 (da) | 2003-05-06 | 2013-02-18 | Gumlink As | Fremgangsmåde til fremstilling af tyggegummigranulater, et gummisammensætningsekstruder- og granuleringssystem og et tyggegummiprodukt |
ES2312741T3 (es) | 2003-05-06 | 2009-03-01 | Gumlink A/S | Procedimiento para producir granulos de goma de mascar y granulos de goma comprimidos, y un equipo para granular goma de mascar. |
GB0330009D0 (en) * | 2003-12-24 | 2004-01-28 | Ferrosan As | Probiotic tablet formulations |
EP1554935A1 (en) * | 2004-01-19 | 2005-07-20 | Gumlink A/S | Layered chewing gum tablet |
JP5179757B2 (ja) * | 2004-02-17 | 2013-04-10 | トランセプト ファーマシューティカルズ, インコーポレイティド | 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法 |
JP4875616B2 (ja) * | 2004-07-06 | 2012-02-15 | ガムリンク エー/エス | 圧縮チューインガムタブレット |
KR100653166B1 (ko) | 2004-12-03 | 2006-12-06 | 김용호 | 기능성 다이어트 필름 조성물 및 제조방법 |
WO2006063189A2 (en) * | 2004-12-10 | 2006-06-15 | Novartis Ag | Multi-layered chewing gum tablet with quick disintegration layer |
EP1848399A1 (en) | 2005-01-28 | 2007-10-31 | Gumlink A/S | A compressed chewing gum table |
EP1998748B1 (en) | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
SE530500C2 (sv) * | 2006-11-16 | 2008-06-24 | Delaval Holding Ab | Anordning och förfarande för provtagning av mjölk |
EP1946751A1 (en) * | 2007-01-22 | 2008-07-23 | Documedica S.A. | Carrageenan-based chewing gum |
US20080286344A1 (en) * | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
CN101861145A (zh) * | 2007-09-18 | 2010-10-13 | 尼科诺瓦姆股份公司 | 包含麦芽糖醇和提供迅速释放尼古丁的稳定的口香糖组合物 |
ES2402130T3 (es) | 2008-05-02 | 2013-04-29 | Kraft Foods Global Brands Llc | Productos de confitería multicapa sin azúcar a base de isomaltosa y métodos para su producción |
CA2736531C (en) * | 2008-09-17 | 2016-10-25 | Niconovum Ab | Process for preparing snuff composition |
CN102448318B (zh) | 2008-11-28 | 2017-07-18 | 亿滋日本株式会社 | 多区域糖食组合物、制品、方法以及设备 |
JP2012515554A (ja) | 2009-01-22 | 2012-07-12 | クラフト・フーズ・グローバル・ブランズ・エルエルシー | 菓子加工 |
EP2233134A1 (en) * | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
WO2011044373A2 (en) | 2009-10-08 | 2011-04-14 | Cadbury Adams Usa Llc | Co-extruded layered candy and gum apparatus and methods |
ES2441738T3 (es) | 2009-10-30 | 2014-02-06 | Intercontinental Great Brands Llc | Dulces sin azúcar, métodos para su preparación y utilización en la preparación de productos de confitería multicapa |
US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
EP2575493B1 (en) * | 2010-06-02 | 2015-12-16 | Intercontinental Great Brands LLC | Confectionery composition and article |
IT1401354B1 (it) * | 2010-08-02 | 2013-07-18 | Quaglia | Sistemi per il rilascio controllato a base di polimeri bioadesivi loro processo di produzione e impieghi clinici |
EP2683251B1 (en) | 2011-03-11 | 2021-08-25 | Intercontinental Great Brands LLC | Method of forming multilayer confectionery |
JP5912180B2 (ja) | 2011-07-21 | 2016-04-27 | インターコンチネンタル グレート ブランズ エルエルシー | チューインガムの形成および冷却のためのシステムおよび方法 |
USD686386S1 (en) | 2011-08-17 | 2013-07-23 | Kraft Foods Global Brands Llc | Confectionary |
USD686388S1 (en) | 2011-08-17 | 2013-07-23 | Kraft Foods Global Brands Llc | Confectionary |
US20130045273A1 (en) * | 2011-08-19 | 2013-02-21 | John Cuomo | Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
US10334867B2 (en) | 2014-03-03 | 2019-07-02 | Intercontinental Great Brands Llc | Method for manufacturing a comestible |
USD779153S1 (en) * | 2014-12-22 | 2017-02-21 | Wm. Wrigley Jr. Company | Strawberry chewing gum |
USD770124S1 (en) * | 2014-12-22 | 2016-11-01 | Wm. Wrigley Jr. Company | Mint chewing gum |
USD778525S1 (en) * | 2014-12-22 | 2017-02-14 | Wm. Wrigley Jr. Company | Blueberry chewing gum |
USD783927S1 (en) * | 2015-08-20 | 2017-04-18 | Wm. Wrigley Jr. Company | Strawberry chewing gum |
USD783926S1 (en) * | 2015-08-20 | 2017-04-18 | Wm. Wrigley Jr. Company | Mint chewing gum |
US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
FR3047898B1 (fr) * | 2016-02-23 | 2020-09-18 | Alpex Pharma | Granules non effervescents contenant de la n-acetylcysteine. |
WO2019060661A1 (en) * | 2017-09-22 | 2019-03-28 | Iowa State University Research Foundation, Inc. | PROBIOTIC COMPOSITIONS FOR THE PRODUCTION OF DOPAMINE |
DK3807260T3 (da) | 2018-06-15 | 2024-10-14 | Reynolds Tobacco Co R | Oprensning af nikotin |
ES2970150T3 (es) * | 2019-03-01 | 2024-05-27 | Nordiccan As | Goma de mascar cannabinoide en comprimidos con una estructura en capas |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU71919A1 (zh) * | 1975-02-26 | 1977-01-06 | ||
US4139589A (en) * | 1975-02-26 | 1979-02-13 | Monique Beringer | Process for the manufacture of a multi-zone tablet and tablet manufactured by this process |
DE2808160A1 (de) * | 1978-02-25 | 1979-08-30 | Nordstroem Rabbe | Neuartige tablette und das verfahren zur herstellung eines solchen presslings |
US4753805A (en) | 1984-01-31 | 1988-06-28 | Warner-Lambert Company | Tabletted chewing gum composition and method of preparation |
CA1240875A (en) | 1984-01-31 | 1988-08-23 | Subraman R. Cherukuri | Tableted chewing gum composition and method of preparation |
IT1180023B (it) | 1984-04-02 | 1987-09-23 | Ruffinatti Srl | Macchina per la preparazione di un prodotto dolciario semilavorato utilizzabile per la produzione di caramelle a ripieno friabile e simili |
EP0370296B1 (en) * | 1988-11-25 | 1994-01-19 | The Procter & Gamble Company | Chewing gum |
JPH075624B2 (ja) * | 1989-01-31 | 1995-01-25 | 東和化成工業株式会社 | ラクチトール三水和物結晶及びそれを含有する含蜜結晶並びにそれらの製造方法 |
JP2896241B2 (ja) | 1991-01-25 | 1999-05-31 | 鐘紡株式会社 | 組み合せ菓子 |
US5286500A (en) | 1992-03-03 | 1994-02-15 | Wm. Wrigley Jr. Company | Wax-free chewing gum base |
US5286502A (en) | 1992-04-21 | 1994-02-15 | Wm. Wrigley Jr. Company | Use of edible film to prolong chewing gum shelf life |
IT1265240B1 (it) * | 1993-11-30 | 1996-10-31 | Ekita Investments Nv | Compressa farmaceutica a rilascio controllato, di forma lenticolare |
IT1274034B (it) * | 1994-07-26 | 1997-07-14 | Applied Pharma Res | Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione |
IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
KR20000010499A (ko) | 1998-07-03 | 2000-02-15 | 야마다 미츠릇 | 약액유량조정장치 및 이것을 구비한 약액주입장치 |
EP1139777B1 (en) * | 1998-12-30 | 2006-03-22 | Wm. Wrigley Jr. Company | Method of coating comestibles with syrup and powder |
US6322806B1 (en) | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
US7087255B2 (en) * | 2000-12-27 | 2006-08-08 | Wm. Wrigley Jr. Company | Chewing gums that provide breath freshening characteristics |
SE0102197D0 (sv) * | 2001-06-20 | 2001-06-20 | Pharmacia Ab | New product and use and manufacture thereof |
US6613346B2 (en) * | 2001-06-28 | 2003-09-02 | Wm. Wrigley, Jr. Company | Chewable product including active ingredient |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
AU2003214016A1 (en) * | 2003-02-04 | 2004-08-30 | Gumlink A/S | Compressed chewing gum tablet |
EP1449525A1 (en) | 2003-02-20 | 2004-08-25 | Cross Chem Llc | chewing gum in the form of multi-layer tablets |
US20050008747A1 (en) * | 2003-07-11 | 2005-01-13 | Barkalow David G. | Method of forming a sugarless coating on chewing gum |
-
2003
- 2003-02-20 EP EP03003813A patent/EP1449525A1/en not_active Withdrawn
-
2004
- 2004-01-20 WO PCT/EP2004/000371 patent/WO2004073691A1/en active IP Right Grant
- 2004-01-20 ES ES04703370T patent/ES2295817T3/es not_active Expired - Lifetime
- 2004-01-20 CN CN2004800044682A patent/CN1750814B/zh not_active Expired - Lifetime
- 2004-01-20 JP JP2006501559A patent/JP5214142B2/ja not_active Expired - Lifetime
- 2004-01-20 AT AT04703370T patent/ATE380021T1/de not_active IP Right Cessation
- 2004-01-20 DE DE602004010493T patent/DE602004010493T2/de not_active Expired - Lifetime
- 2004-01-20 US US10/545,348 patent/US9216157B2/en active Active
- 2004-01-20 CA CA2518528A patent/CA2518528C/en not_active Expired - Lifetime
- 2004-01-20 EP EP04703370A patent/EP1594478B1/en not_active Revoked
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102480990A (zh) * | 2009-08-19 | 2012-05-30 | 狮王株式会社 | 糖衣口香糖及糖衣口香糖的制造方法 |
CN102480990B (zh) * | 2009-08-19 | 2013-10-16 | 狮王株式会社 | 糖衣口香糖及糖衣口香糖的制造方法 |
CN102599324A (zh) * | 2012-03-16 | 2012-07-25 | 常熟市汇丰食品有限公司 | 一种芳香植物口香糖及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060204451A1 (en) | 2006-09-14 |
ATE380021T1 (de) | 2007-12-15 |
DE602004010493T2 (de) | 2008-12-11 |
JP2006520751A (ja) | 2006-09-14 |
DE602004010493D1 (de) | 2008-01-17 |
ES2295817T3 (es) | 2008-04-16 |
CA2518528C (en) | 2012-11-06 |
WO2004073691A1 (en) | 2004-09-02 |
EP1594478A1 (en) | 2005-11-16 |
CN1750814B (zh) | 2010-05-12 |
EP1594478B1 (en) | 2007-12-05 |
CA2518528A1 (en) | 2004-09-02 |
JP5214142B2 (ja) | 2013-06-19 |
EP1449525A1 (en) | 2004-08-25 |
US9216157B2 (en) | 2015-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1750814A (zh) | 多层片形式的口香糖 | |
CN1633242A (zh) | 压缩口香糖 | |
CN1146401C (zh) | 生物粘着固体剂型 | |
EP1957110B1 (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
CN1633241A (zh) | 压缩口香糖片ii | |
CN1596100A (zh) | 可食用组合物及含可食用外壳的制剂 | |
CN1086708A (zh) | 具有两阶段释放特征的固体药物及其生产方法 | |
CN1738539A (zh) | 压缩口香糖片 | |
CN101039587A (zh) | 糖果产品 | |
CN1585650A (zh) | 可食性薄膜 | |
CN1615124A (zh) | 配方 | |
JP2008504828A (ja) | 圧縮チューインガムタブレット | |
CN1622810A (zh) | 孕酮口服药物传输系统 | |
JP2014532041A (ja) | 動物への経口投与用組成物、その製造方法およびその使用 | |
CN1662225A (zh) | 气爆式口服剂型 | |
CN1158936C (zh) | 自口香糖中的亲脂活性剂释放 | |
CN1721467A (zh) | 片剂赋形剂 | |
CN1819772A (zh) | 无粘性的口香糖口胶基质 | |
CN1889935A (zh) | 延迟释放医药剂型 | |
CN1546033A (zh) | 美洛昔康口腔崩解片及其制备方法 | |
CN1708231A (zh) | 胶基组合物 | |
CN1499961A (zh) | 一种在胃液中漂浮并多脉冲释放活性物质的药用片剂系统、该系统和该系统包封物的制备方法 | |
CN1857229A (zh) | 适合儿童服用的含药物糖丸及其制备方法 | |
CN1726027A (zh) | 包含曲马多和托吡酯的控释制剂 | |
CN1149980C (zh) | 以未水解明胶作为基质、含有大量食用油填料的喷雾干燥粉末以及制备所述可制片喷雾干燥粉末的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20100512 |